カテゴリ： GlobalData, カナダ, 企業調査

Critical Outcome Technologies Inc (COT)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Critical Outcome Technologies Inc (COT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013167
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Critical Outcome Technologies Inc (COTI) is a biopharmaceutical company that develops targeted therapeutics with focus on oncology. The company’s lead program COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological cancers. It also offers COTI-219, COTI-4 and COTI-58 for small cell lung cancer, and other products for Alzheimer’s disease, HIV integrase inhibitors, and multiple sclerosis. COTI uses its proprietary technology Chemsas, a multistage computational platform technology based on hybrid of machine learning technologies and proprietary algorithms which allows accurate prediction of biological activity from the molecular structure. The company offers generating of pipelines for pharmaceutical and biotechnology companies. COTI is headquartered in London, Ontario, Canada.

Critical Outcome Technologies Inc (COT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Critical Outcome Technologies Plans To Enter Into Co-Development Agreement 17
Critical Outcome Technologies and Xcelience Enter into Agreement 18
Equity Offering 19
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 20
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 23
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 24
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 26
Critical Outcome Raises USD0.4 Million in Private Placement of Units 27
Critical Outcome Raises USD0.22 Million in Private Placement of Units 28
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 29
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 31
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 32
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 34
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 35
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 36
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.36 Million 37
Debt Offering 39
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 39
Critical Outcome Technologies Inc – Key Competitors 40
Critical Outcome Technologies Inc – Key Employees 41
Critical Outcome Technologies Inc – Locations And Subsidiaries 42
Head Office 42
Recent Developments 43
Financial Announcements 43
Sep 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results 43
Aug 28, 2017: Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results 45
Mar 16, 2017: Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017 47
Dec 19, 2016: Critical Outcome Technologies Reports Second Quarter Financial and Operating Results for Fiscal 2017 48
Sep 29, 2016: Critical Outcome Technologies Reports Fiscal 2017 First Quarter Financial and Operating Results 49
Aug 03, 2016: Critical Outcome Technologies Reports Year-End Financial & Operating Results 50
Mar 11, 2016: Critical Outcome Technologies Reports Fiscal 2016 Third Quarter Financial and Operating Results 52
Corporate Communications 53
May 11, 2017: Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer 53
Feb 01, 2017: Critical Outcome Technologies Announces Departure of Chief Scientific Officer 54
Dec 08, 2016: Critical Outcome Technologies appoints new CEO 55
Dec 08, 2016: Critical Outcome Technologies Appoints Alison Silva as Chief Executive Officer 56
Sep 13, 2016: Critical Outcome Appoints Dr. Bharatt Chowrira to Its Board of Directors 57
Jun 15, 2016: Critical Outcome Technologies Appoints Experienced Industry Executive as New President 58
Product News 59
Mar 14, 2016: Critical Outcome Launches Rosalind — A Precision Medicine Platform Designed to Provide Cancer Treatment Options 59
Other Significant Developments 60
Oct 14, 2016: Critical Outcome Technologies Provides Update on Recent Achievements and Future Strategic Objectives at Annual General Meeting 60
Mar 22, 2016: Critical Outcome Technologies Provides Market Update 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Critical Outcome Technologies Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Critical Outcome Technologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Critical Outcome Technologies Plans To Enter Into Co-Development Agreement 17
Critical Outcome Technologies and Xcelience Enter into Agreement 18
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 20
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 23
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 24
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 26
Critical Outcome Raises USD0.4 Million in Private Placement of Units 27
Critical Outcome Raises USD0.22 Million in Private Placement of Units 28
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 29
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 31
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 32
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 34
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 35
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 36
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.36 Million 37
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 39
Critical Outcome Technologies Inc, Key Competitors 40
Critical Outcome Technologies Inc, Key Employees 41

★海外企業調査レポート[Critical Outcome Technologies Inc (COT)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bergman & Beving AB：企業の戦略・SWOT・財務情報
    Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report Summary Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bristol-Myers Squibb Co (BMY)-医療機器分野：企業M&A・提携分析
    Summary Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is in cancer, cardiovascular, immunoscience and …
  • Revenio Group Oyj (REG1V)：企業の財務・戦略的SWOT分析
    Revenio Group Oyj (REG1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MEDICREA Group (ALMED)：医療機器：M&Aディール及び事業提携情報
    Summary MEDICREA Group (MEDICREA) is a medical equipment company that provides surgical solutions to neurosurgeons and orthopedic surgeons. The company designs, manufactures and distributes proprietary technologies related to patient specific spinal surgery. It offers products such as polyaxial spin …
  • EndoStim Inc-医療機器分野：企業M&A・提携分析
    Summary EndoStim Inc (EndoStim) is a medical device company that offers therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through el …
  • Itochu Corp (8001)：石油・ガス：M&Aディール及び事業提携情報
    Summary Itochu Corp (Itochu) is a trading company. It offers domestic trading, import and export, and overseas trading. The company trades in products such as textile, machinery, metals, minerals, energy, chemicals, food, general products, information and communications technology, realty, insurance …
  • PTT Public Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    PTT Public Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary PTT Public Co Ltd (PTT) is a state-owned integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carr …
  • Birks Group Inc (BGI)：企業の財務・戦略的SWOT分析
    Birks Group Inc (BGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Snyder’s-Lance Inc：企業の戦略的SWOT分析
    Snyder's-Lance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Realtek Semiconductor Corp. (2379)：企業の財務・戦略的SWOT分析
    Realtek Semiconductor Corp. (2379) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Stantec Inc：企業のM&A・事業提携・投資動向
    Stantec Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stantec Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Elektrani na Makedonija：企業の戦略的SWOT分析
    Elektrani na Makedonija - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Meritor, Inc.：企業の戦略・SWOT・財務分析
    Meritor, Inc. - Strategy, SWOT and Corporate Finance Report Summary Meritor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Trimble Inc：企業の戦略・SWOT・財務情報
    Trimble Inc - Strategy, SWOT and Corporate Finance Report Summary Trimble Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nexstar Media Group, Inc. (NXST)：企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Chiesi Farmaceutici SpA：製薬・医療：M&Aディール及び事業提携情報
    Summary Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, …
  • China North Industries Group Corp：企業の戦略的SWOT分析
    China North Industries Group Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • New York Blood Center：製薬・医療：M&Aディール及び事業提携情報
    Summary New York Blood Center (NYBC) is a non-profit healthcare organization that offers blood collection and distribution. The organization's blood products comprise red blood cells, plasma products, platelets, frozen blood and washed products, whole blood and granulocytes. It offers medical servic …
  • Immune Therapeutics Inc (IMUN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Immune Therapeutics Inc (IMUN), formerly pH Environmental Inc, is a specialty pharmaceutical company that discovers, develops and commercializes patented therapies and technology such as Lodonal, LDN, CAR-T and MENK. The company’s patented therapies are focused on the activation and re-balan …
  • Valeo SA (FR)：企業の財務・戦略的SWOT分析
    Valeo SA (FR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆